Filing Details

Accession Number:
0001104659-22-103860
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-09-29 06:14:47
Reporting Period:
2022-09-28
Accepted Time:
2022-09-29 06:14:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1740279 In8Bio Inc. INAB () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1714576 Bios Fund Ii, Lp C/O Bios Equity Partners
1751 River Run, Suite 400
Fort Worth TX 76107
Yes No Yes No
1716869 Bios Fund Ii Qp, Lp C/O Bios Equity Partners
1751 River Run, Suite 400
Fort Worth TX 76107
Yes No Yes No
1728851 Bios Fund Ii Nt, Lp C/O Bios Equity Partners
1751 River Run, Suite 400
Fort Worth TX 76107
Yes No Yes No
1740029 Bios Incysus Co-Invest I, Lp C/O Bios Equity Partners
1751 River Run, Suite 400
Fort Worth TX 76107
Yes No Yes No
1789490 G.l. Aaron Fletcher C/O Bios Equity Partners
1751 River Run, Suite 400
Fort Worth TX 76107
Yes No Yes No
1791910 Bios Fund Iii Nt, Lp C/O Bios Equity Partners
1751 River Run, Suite 400
Fort Worth TX 76107
Yes No Yes No
1791916 Bios Fund Iii Qp, Lp C/O Bios Equity Partners
1751 River Run, Suite 400
Fort Worth TX 76107
Yes No Yes No
1791917 Bios Fund Iii, Lp C/O Bios Equity Partners
1751 River Run, Suite 400
Fort Worth TX 76107
Yes No Yes No
1813844 Bios Advisors Gp, Llc C/O Bios Equity Partners
1751 River Run, Suite 400
Fort Worth TX 76107
Yes No Yes No
1813845 Bios Capital Management, Lp C/O Bios Equity Partners
1751 River Run, Suite 400
Fort Worth TX 76107
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-09-28 3,070 $2.02 592,766 No 5 P Indirect See footnote
Common Stock Acquisiton 2022-09-28 19,017 $2.02 3,670,545 No 5 P Indirect See footnote
Common Stock Acquisiton 2022-09-28 2,913 $2.02 561,989 No 5 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 P Indirect See footnote
No 5 P Indirect See footnote
No 5 P Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 574,432 Indirect See footnote
Common Stock 1,876,624 Indirect See footnote
Common Stock 251,211 Indirect See footnote
Common Stock 997,433 Indirect See footnote
Footnotes
  1. Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and BIOS Incysus Co-Invest I, LP ("BIOS Incysus"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Bios Capital Management, LP ("Bios Management") and Cavu Management, LP ("Cavu Management") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management. Cavu Advisors LLC ("Cavu Advisors") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr.
  2. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
  3. Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
  4. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
  5. The securities are directly held by Bios Fund III NT.
  6. The securities are directly held by Bios Fund III QP.
  7. The securities are directly held by Bios Fund III.
  8. The securities are directly held by Bios Fund II.
  9. The securities are directly held by Bios Fund II QP.
  10. The securities are directly held by Bios Fund II NT.
  11. The securities are directly held by BIOS Incysus.
  12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $2.15, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4.